检索范围:
排序: 展示方式:
Prospects of immunotherapy for cancer
Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 1-2 doi: 10.1007/s11684-019-0691-y
Immunometabolism: a new dimension in immunotherapy resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 585-616 doi: 10.1007/s11684-023-1012-z
关键词: immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
《医学前沿(英文)》 2011年 第5卷 第4期 页码 323-332 doi: 10.1007/s11684-011-0172-4
Challenges of NK cell-based immunotherapy in the new era
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 440-450 doi: tzg@ustc.edu.cn
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
关键词: natural killer cells immunotherapy adoptive transfer genetic modification immune checkpoint inhibitor
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
《医学前沿(英文)》 2021年 第15卷 第6期 页码 783-804 doi: 10.1007/s11684-021-0904-z
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
《医学前沿(英文)》 2007年 第1卷 第1期 页码 11-19 doi: 10.1007/s11684-007-0003-9
关键词: development conventional identification elucidation Successful immunotherapy
调节性T细胞及其在抗肿瘤免疫疗法中的临床应用 Review
解丰, 梁瑞, 李丹, 李斌
《工程(英文)》 2019年 第5卷 第1期 页码 132-139 doi: 10.1016/j.eng.2018.12.002
癌症是可能危及生命的疾病,特点在于肿瘤细胞在宿主身上无限增殖。最近,因其具有预防肿瘤进展和转移的巨大潜力,免疫疗法受到越来越多研究者的关注。调节性T 细胞(Treg)是对维持宿主免疫稳态起重要作用的抑制性CD4+ T 细胞的一个亚群。调节性T 细胞缺陷可引起严重的自身免疫、过敏和自身炎症等疾病。调节性T 细胞通常富集在肿瘤微环境中,而大量免疫抑制调节性T细胞往往表明预后较差。因此,人们对调节性T 细胞的功能及其在抗肿瘤免疫疗法中的临床应用再次产生了兴趣。越来越多的策略关注调节性T 细胞的消耗,这在抗肿瘤免疫方面似乎有效。预计调节性T 细胞靶向策略与其他疗法(如嵌合抗原受体T 细胞疗法或免疫检查点阻断)联用将为提高抗肿瘤疗效带来重大机遇。
Chuangnian Zhang, Ying Dong, Jing Gao, Xiaoli Wang, Yanjun Jiang
《化学科学与工程前沿(英文)》 2021年 第15卷 第5期 页码 1296-1311 doi: 10.1007/s11705-020-2034-6
关键词: silica nanoflower antigen delivery cancer immunotherapy nanovaccine
《医学前沿(英文)》 2022年 第16卷 第1期 页码 139-149 doi: 10.1007/s11684-021-0835-8
关键词: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
Activation of phagocytosis by immune checkpoint blockade
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 473-480 doi: 10.1007/s11684-018-0657-5
Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.
关键词: CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage
基于自然杀伤细胞的癌症免疫疗法的进展和前景 Review
胡渊, 田志刚, 张彩
《工程(英文)》 2019年 第5卷 第1期 页码 106-114 doi: 10.1016/j.eng.2018.11.015
自然杀伤(natural killer,NK)细胞是重要的先天免疫细胞,位于机体抵御病毒感染和癌症的第一道防线。尽管自然杀伤细胞可以区分“自身”和“非自身”,识别异常细胞,并实时清除恶性转化的细胞和肿瘤,但肿瘤也形成了一些逃逸自然杀伤细胞攻击的策略。这些策略包括:上调自然杀伤细胞抑制性受体的配体,产生可溶性分子或免疫抑制因子。目前,临床试验正在应用各种类型的自然杀伤细胞治疗不同类型的肿瘤,包括自体或同种异体自然杀伤细胞、脐带血(umbilical cord blood,UCB)或诱导性多能干细胞(induced pluripotent stem cell,iPSC)来源的自然杀伤细胞、记忆样自然杀伤细胞和自然杀伤细胞系NK-92 细胞。近来,嵌合抗原受体(chimeric antigen receptor,CAR)修饰的自然杀伤细胞因其再导向特异性和有效的抗肿瘤活性而展现出巨大潜力。文中总结了肿瘤逃逸自然杀伤细胞识别的机制、自然杀伤细胞免疫疗法的现状和进展、提升自然杀伤细胞体内抗肿瘤能力的途径以及该领域在临床实践中所面临的重大挑战。
Translational medicine in hepatocellular carcinoma
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 122-133 doi: 10.1007/s11684-012-0193-7
Hepatocellular carcinoma (HCC) is a highly complex disease that is generally resistant to commonly used chemotherapy and radiotherapy. Consequently, there is an urgent need for the development of new treatment strategies for this devastating disease. In the past decade, tremendous progress has been achieved in the molecular stratification of HCCs for diagnosis, prognosis, and therapeutic decision-making. To date, the molecular classification of HCCs has been carried out through transcriptomic, genetic and epigenetic profiling of tumors. Such research has led to identification of several potential molecular targets in HCC, and subsequently, development of novel systemic agents for the treatment of HCC has begun in earnest. In this article, we review the current knowledge of the molecular pathogenesis of HCC and outline potential areas for application of this knowledge in a clinical setting. As a typical virus and inflammation-associated cancer, both host immune response and tumor microenvironment have crucial roles in HCC pathogenesis. In addition, we examine the potential of immunotherapy and strategies targeting various components of the tumor microenvironment, as well as novel molecular and cellular targets in HCC such as cancer stem cells.
关键词: hepatocellular carcinoma molecular classification molecular targeted therapies tumor microenvironment immunotherapy
李永洁,杨俊涛,杜建
《中国工程科学》 2018年 第20卷 第6期 页码 64-68 doi: 10.15302/J-SSCAE-2018.06.010
随着医学与现代信息技术、材料科技等技术的深度交叉融合,极大地促进了医学科技的发展,疾病诊断和治疗模式发生革命性的变化。本文主要从医学领域的肿瘤免疫治疗、基因编辑技术、医学人工智能、合成生物学技术和干细胞与转化医学五个技术方向,分析评价其发展态势;结合文献、智库报告和专家观点,对医学科技发展方向进行初探,提出重视医学基础研究投入、优化医学科技战略顶层设计、完善政策及监管体系等政策建议。
Emerging immunological strategies: recent advances and future directions
《医学前沿(英文)》 2021年 第15卷 第6期 页码 805-828 doi: 10.1007/s11684-021-0886-x
关键词: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer vaccines
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
《医学前沿(英文)》 2022年 第16卷 第3期 页码 307-321 doi: 10.1007/s11684-022-0927-0
关键词: tumor immunotherapy immune checkpoint inhibitor antibiotics gut microbiota drug–drug interaction
标题 作者 时间 类型 操作
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
期刊论文
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
期刊论文
and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy
期刊论文